A diagnostic test to identify the genetic cause of unexplained illness in infants admitted to the NICU.

GenomeScope NICU

GenomeScope NICU Is a Rapid Genomic Test to Analyze Gene Variations in Critically Ill Infants below 24 Months of Age. The Test Boasts a Short Turnaround Time, Enabling Faster Diagnosis That Can Change the Course of Treatment in Newborns Admitted to the NICU.
  • Sample Type : Heel-Prick
  • Collection Type : Doctor
  • Results : Within 5 days
  • Genes Tested : 6800+
₹45,000.00
How Does It Work?

Order Online

Book your GenomeScope NICU test online.

Sample Collection

A trained paramedic collects the blood sample either via heel-prick or through the cord blood soon after the baby’s birth.

Receive Digital Results

Within 5 days, you’ll receive the results and useful insights on your personalised dashboard.

Follow Up

- If tested positive, schedule a virtual consultation with our genetic counselor to understand your results better.

- If tested negative, consult a physician for further testing. Exome re-analysis is recommended in case of future presentation of symptoms.

Digital Results - Your Smart Report

Customised Dashboard Experience:

Along with an interactive, user-friendly experience, we also offer you the complete screening test insight in the form of smart reports.

SMART Reports:

Empowering you with the right information, our SMART reports are:

  • Easy-to-understand
  • Reliable
  • Easy to share in just a few clicks!

Recommendations from Genetic Counselors

We understand the importance of receiving expert advice at the right time. That’s why we don’t just provide your test results and leave it at that. Our in-house team of genetic counselors interprets the out-of-range results and provides you with tailored advice.

Why Choose LifeCell?

NABL & CAP Certified

Our labs are NABL and CAP certified. This means they have to meet high testing standards and submit themselves to regular inspections.

Privacy & Confidentiality

Your privacy is our priority. We use state-of-the-art technology to ensure your data is stored securely, and under no circumstance do we ever sell your data.

Certified Results

All our test reports are reviewed & approved by board-certified geneticists and genetic counselors.

Hear From Our Doctors And Customers

Frequently Asked Questions

Wish To Know More?

Newborns and children under 24 months presented with life-threatening conditions need a fast and precise diagnosis to ensure rapid and efficient therapeutic initiation. By nature of being rare diseases, the symptoms caused by them can often look similar to more common conditions thereby, being overlooked or mistaken. Failure to diagnose them slows down the process of being able to access the most appropriate care and treatment, leading to complications or even death. Early diagnosis and faster meaningful treatment can save hospital costs and allows an improved quality of life for the child.

Here are some important statistics highlighting the importance of genetic testing for newborns Without the power of genetic testing, it takes about 7.3 physicians and 4 years for the diagnosis of a rare disorder. 1 in 3 babies admitted in Neonatal ICU has a genetic disease. 75% of rare disorders affect children. 30% of babies with rare diseases die before their first birthday. 80% of rare diseases have a genetic origin.

Yes! In September 2019, the Indian government inaugurated five new molecular diagnostics centres all over the country as part of the Unique Methods of Management and Treatment of Inherited Disorders (UMMID) program to tackle the menace of genetic diseases in newborns. In India’s urban areas, congenital malformations and genetic disorders are the third most common cause of mortality in newborns. With a very large population and high birth rate,and consanguineous marriage favored in many communities, prevalence of genetic disorders is high in India. UMMID initiative aims to establish NIDAN (National Inherited Diseases Administration) kendras to provide counselling,prenatal testing and diagnosis, management, and multidisciplinary care in Government Hospitals wherein the influx of patients is more. In the UK, effective Nov 2019, the National Health Services (NHS) is beginning a scheme to test babies' DNA at birth to protect them from inherited diseases, starting with a pilot scheme of 20,000 children. Earlier in April 2019, US legislators have introduced a bill ‘Ending the Diagnostic Odyssey Act,’ to provide genome sequencing for certain undiagnosed children.

Heart conditions like aortic aneurysms, arrhythmias, cardiomyopathies, hereditary childhood cancers like retinoblastoma, neurofibromatosis, endocrine neoplasia, sensorineural hearing loss, pulmonary hypertension, vision loss,SCID, bowel hypomotility / obstruction, seizures, hyperbilirubinemia, hypothyroidism, anemia, thrombocytopenia, inborn errors of metabolism, neonatal respiratory distress, skeletal dysplasia, dermatological disorders, thrombophilia,congenital liver disease and many more.

The term newborn screening refers to screening newborns for treatable inherited conditions soon after birth. It is a biochemical screening test for approximately only 50 conditions. It requires additional confirmation via genetics,which may require extra sample, time and can cause interim anxiety. Also, missed diagnosis may lead to overall increased poorer outcomes. Genome-Scope on the other hand is a diagnostic test rather than a conventional screening test. The analysis of DNA offers us a broader view of diseases which may not be identifiable by blood biochemistry. It tests for over 4000 genes related to inherited newborn and early childhood disorders, and the results are with >95% accuracy using the NGS based advanced technology.

Talk To Our Experts, We're Here To Help

Curious To Learn More About Our Products Or Not Sure Where To Begin Your Journey?

Featured Blog

GenomeScope NICU

GenomeScope NICU